

London North West Healthcare



## Managing abnormal LFTs

Dr Simon Gabe Consultant Gastroenterologist St Mark's Hospital







## It depends ...

# ShortLongtermtermPNPN

- VALERAN

## Questions

## How common are abnormal LFTs in patients on IVN?

## Is it the parenteral nutrition?





Author	Study	% Elevated		
		AST	Alk Phos	Bil
Lindor et al. 1979	2 weeks PN (high glucose & no lipid)	68%	54%	21%
Clarke et al. 1991	4 weeks PN (more balanced PN)	27%	32%	31%

And the Party of the Party of the

Short term PN

## Is it the parenteral nutrition?







Liver biopsies • 93 patients on TPN

• 35 matched controls

Assessment

- 19 histological grades
- 27 clinical variables

Results: abnormal hepatic histology correlated with

- Pre-existing liver disease
- Abdominal sepsis
- Renal failure
- Blood transfusion

Histology DID NOT correlate with TPN administration

## Abnormal LFTs & short term PN

□ 58 patients receiving PN (M:F 36:22)

□ 48 (83%) fistula, obstruction, ileus, failed EN

Abn LFTs before PN started (34% patients)

- 60% LFTs worsened on PN
- 30% LFTs resolved on PN

Abn LFTs while on PN (9% patients)

- 46% sepsis
- 24% underlying liver disease

Baker & Nightingale, Clin Nutr 2004;23:864

#### Long term PN

## Abnormal LFTs & long term PN

Author	No. HPN patients	Abn LFTs	Severe liver disease
Luman et al, 2002	107	48%	0%
Salvino et al, 2006	162	95%	4%
Lloyd et al, 2008	113	24% CC	
Cavicci et al, 2000	90	65% CC	26% at 2 years 50% at 5 years
Chan et al, 1999	42		14%
lto & Shills, 1991	16		19%

STATISTICS.

TAXABLE PARTY


CC = chronic cholestasis

## Questions


# What are the causes of abnormal liver function?

## What can to do to change this?

#### Short-term PN





## What do I do?



Distance of the local distance of the

- VIET HEAT






## What is evil .....

## More parenteral lipid?

## More parenteral calories?




NAME AND ADDRESS OF

- VERENA

#### Lindor et al, 1979

Large amount of energy supplied as glucose (>GOR) Associated with steatosis




Long term PN


## Parenteral lipid emulsions

NAME AND ADDRESS OF

- CELERA


Generation	Description	Lipid types	Brands	
1 <sup>st</sup>	Conventional lipid	LCT (soybean oil) LCT (soy/safflower oil)	Intralipid	
2 <sup>nd</sup>	Lipid emulsions with reduced PUFA	Structured lipids (MCT/LCT) Olive oil based emulsion	Structolipid Clinoleic	
3 <sup>rd</sup>	Lipid emulsions with reduced PUFA & specific ω6/ω3 FA ratio	Fish oil Soy/MCT/olive oil/fish oil	Omegaven SMOF	





Klek et al, Clin Nutr 2013;32:224-231


### Fish oil effect: >1 mechanism





- Vale Halet

Long term PN

## **Reversal of cholestasis**








Best way to achieve <1g/kg/day is NO DAILY LIPIDS</p>

Could use

10% lipid emulsion

Less 20% lipid

but bag is less stable



## Questions

# Do you give cyclical parenteral nutrition?

## Fibroscan or liver biopsy?


## PN: continuous vs cyclical

## **Continuous PN**

- Jeopardizes hepatic mitochondrial re-energization
- The function of the second se

## Circadian PN pattern

 May reduce the risk of postischaemic mitochondrial liver dysfunction Liver glygogen after 5 days TPN




#### Liver biopsy Elastography Which one? Higher risk Interpretation procedure difficult More Not invasive definitive diagnosis

NAME AND ADDRESS OF

## FibroScan stiffness

Significant correlation with bilirubin & histological cholestasis
No correlation with histologic fibrosis



Fibroscan value and Brunt stage (histological fibrosis score)

Fibroscan value and histological cholestasis grade

## How can this affect your practice?



#### Acute IF (Type 1)

- Look for causes other than the IV nutrition
- Reasonable to give daily lipid
- Do not overfeed
- Best type of lipid?
  - Need more comparative studies
  - Anti-inflammatory & anti-oxidative properties of fish oil is attractive

#### Chronic IF (Type 2-3)

- Key message is to give lipid according to EFA requirements (<1g/kg/day)</li>
- **Do not** increase glucose calories as a result
- IFALD patients
  - Decrease further/stop lipid
  - Use 2<sup>nd</sup> or 3<sup>rd</sup> generation lipid but stability issues may mean that the lipid is given separately

